The Cusp expands hormone menopause test kits into 7 states

It wasn’t until the femtech startup The Cusp began offering hormone test kits this summer to women experiencing menopause symptoms that it finally found what it was looking for: product-market fit. 

In the months following the hormone test kit launch, the San Francisco startup has sold thousands of test kits and has grown at a rate between 15% and 25% a week, said Dr. Taylor Sittler, co-founder and CEO of The Cusp. 

The hormone test, combined with a questionnaire, can estimate where a woman is on her transition into menopause, by measuring levels of Anti-Mullerian hormone (AMH), Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH). After the lab results are completed, the patient gets a 15-minute visit with a provider to go over the results. Of those who purchase the test, 25% to 50% sign up for a monthly subscription to The Cusp’s telemedicine platform, which includes prescriptions, supplements, and digital and virtual visits with a menopause expert. 

Image from brand.

The test kit is on sale from its normal $99 price to $49. A subscription to The Cusp costs $75 a month.

Patients can use their FSA and HSA to pay for the visits and insurance will cover the prescriptions as well as any laboratory testing that’s done.

It turns out, according to the company, that the more severe the symptoms a person experiences the more likely a patient will sign up for the monthly services, which aim to treat symptoms and improve the patient’s quality of life during this inevitable and oftentimes challenging transition.

A woman can experience menopause symptoms for 20 to 30 years. About 85% of women in perimenopause — the transition into menopause — will experience some symptoms, such as hot flashes, irregular periods, painful sex or mood swings.

To reach more women, The Cusp has recently expanded its services from its initial market in California into six other states: Arizona, Texas, Illinois, Georgia, Florida and New York. 

The market for menopause care is huge, they say, as there are a limited number of menopause providers who are certified by North American Menopause Society. 

“You’re talking about 70 to 90 providers and millions of women,” Sittler said. “There’s a huge mismatch.”

With a virtual platform and a hormone test kit, Sittler sees his company as a scalable solution to addressing a huge gap in care.

Sittler, with a background in software and medicine, founded The Cusp in 2018, as a way to reimagine menopause care and increase access to an area of medicine that he says is widely underserved. The Cusp is now available in seven states, has 21 employees and has raised a $4.2 million seed round. 

“There are some tweaks that we want to make to the service and cost structure and things like that, but we’re close to being able to really scale this,” he said, adding that they plan to raise additional capital to help them get to the Series A round. 

Article taken from Bizjournal.


Share on facebook
Share on twitter
Share on linkedin